Lonza News
3 articles
growth-positive
Lonza and Sheba Medical Center Demonstrate Successful Cell Therapy Results with Cocoon Automated Platform
Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform. Three out of four patients showed complete responses. The Cocoon platform is flexible and capable of manufacturing immunotherapies for personalized point-of-contact treatment. Lonza and Sheba Medical Center plan to dose additional patients using the Cocoon platform. The collaboration between Lonza and Sheba Medical Center aims to revolutionize the production of patient-scale cell therapy and make it available to more patients in need.
PartnersCustomers
growth-positive
Lonza Opens Israeli Innovation Center
Lonza has opened its collaborative innovation center in Israel, which will serve as the companys link to local collaborations and partnerships with academic institutes, hospitals, and startups. The center focuses on three main research areas: expression systems and synthetic biology, cell and gene therapies, and data acquisition and analytics. It is headed by biochemist Frida Grynspan-Gotlieb.
Partners
growth-positive
Lonza Announces Formation of New Center in Israel
Lonza has announced the establishment of the Lonza Collaborative Innovation Center (CIC) in Israel. The CIC aims to accelerate R&D projects and tap into transformative biological and manufacturing capabilities. Lonza plans to hire 15-20 staff members in 2018 to leverage Israels scientific strengths. The company has already signed memorandums of understanding and conducted talent scouting at various Israeli institutions. Eytan Abraham and Roee Atlas will be responsible for setting up and managing the center, respectively.
PartnersExpand